S.B. 3160 Summary

• Establishes a therapeutic psilocybin working group within the Department of Health to examine the medicinal and therapeutic effects of psilocybin and develop a long-term strategic plan for safe, accessible, and affordable psilocybin-based products for adults 21 and older.

• Working group shall examine federal, state, and local laws regarding therapeutic psilocybin use; review medical and scientific research on psilocybin's safety and efficacy for treating mental health conditions including depression, anxiety, addiction, and end-of-life distress; and study prescribing requirements in jurisdictions where therapeutic psilocybin is available.

• Working group membership includes the Director of Health (chair), Attorney General, dean of the John A. Burns School of Medicine, legislative health and judiciary committee chairs, Hawaii State Council on Mental Health chairperson, and licensed physicians and psychiatrists invited by the chairperson.

• Working group members serve without compensation but receive reimbursement for necessary expenses and are exempt from Hawaii's conflict of interest laws (Chapter 84, HRS) related to their participation.

• Working group must submit findings, recommendations, and proposed legislation to the legislature no later than 20 days before the 2023 regular session; working group dissolves June 30, 2023; Act takes effect January 1, 2050.